Touchlight, an innovation-driven CDMO pioneering enzymatic DNA production to enable the genetic medicine revolution, announced a license agre...
Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ® Funding will support clin...
Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced the completion of $35 Mill...
Biotechnology company Apriori Bio has been awarded US $1.1 million from CEPI to advance its biology-informed artificial intelligence platform Octavi...
Valneva SE , a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Val...
Moderna, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...
Regulatory review of the single-dose CHIKV VLP vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individua...
The first participants have been dosed in SAFYR, a Phase I clinical trial to test the safety and efficacy of two prophylactic vaccines developed with A...
• Consortium formed between WACKER & CordenPharma has officially entered the pandemic readiness state as of 1 June 2024 to produ...
Moderna, announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its primary efficacy endpoint, demon...
Amidst growing concerns from U.S. federal, state and local agencies over Highly Pathogenic Avian Influenza (HPAI) A (H5N1) detections in dairy cows, Inte...
BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, fo...
CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, announced that its UCLA res...
Moderna, Inc. received notification from the U.S. Food and Drug Administration (FDA) regarding a delay in the review process for its investigational respir...
© 2024 Biopharma Boardroom. All Rights Reserved.
